The Technical Analyst
Bionano Genomics Inc [BNGO]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Bionano Genomics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
3.57% $0.786
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 48.13 mill |
| EPS: | -6.81 |
| P/E: | -0.120 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 61.23 mill |
| Avg Daily Volume: | 1.533 mill |
| RATING 2024-04-26 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.120 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.120 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.701 - 0.871 ( +/- 10.81%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-15 | Chaubey Alka | Sell | 1 081 | Common Stock |
| 2024-02-15 | Oldakowski Mark | Sell | 1 229 | Common Stock |
| 2024-02-15 | Holmlin R. Erik | Sell | 3 073 | Common Stock |
| 2024-02-15 | Dixon Jonathan V. | Sell | 402 | Common Stock |
| 2023-09-18 | Oldakowski Mark | Buy | 20 000 | Common Stock |
| INSIDER POWER |
|---|
| 83.54 |
| Last 99 transactions |
| Buy: 20 105 134 | Sell: 833 309 |
Forecast:
16:00 - $0.786
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.786
Forecast 2: 16:00 - $0.786
Forecast 3: 16:00 - $0.786
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.786 (3.57% ) |
| Volume | 0.549 mill |
| Avg. Vol. | 1.533 mill |
| % of Avg. Vol | 35.84 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BNGO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $1.185 | N/A | Active |
|---|
BNGO
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Latest Press Releases
2024-04-11 08:00:00 - Press Release
Bionano Announces Publication Showing That Ogm Detects Over 1250 Structural Variants, Including 56 Gene Fusions, In Pediatric Leukemia That Were Missed By Whole Genome Sequencing
Researchers used optical genome mapping in addition to whole genome sequencing in pediatric leukemia samples and identified additional structural variants.
2024-04-04 13:44:00 - Press Release
Bionano Announces $10 Million Registered Direct Offering Priced At-the-market Under Nasdaq Rules
San diego, april 04, 2024 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 8,733,626 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 8,733,626 shares of its common stock at an offering price of $1.145 per share of common stock (or per common stock equivalent in lieu thereof) and accompanying warrant, in a registered direct offering priced at-the-market under nasdaq rules. the warrants will be exercisable immediately upon issuance, have an exercise price of $1.02 per share and expire five years from the date of issuance.
2024-04-03 08:00:00 - Press Release
Bionano Announces Publication Showing That Ogm Identifies Genetic Aberrations In Sarcoma Samples That May Lead To Improved Diagnosis But Were Missed By Classical Cytogenetics
San diego, april 03, 2024 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo), today announced the publication of a peer-reviewed study that compared optical genome mapping (ogm) to classical cytogenetic techniques used for analysis of solid tumor cancer samples consisting of soft tissue and bone sarcomas, including fluorescence in situ hybridization (fish) and karyotyping (kt). ogm demonstrated high levels of concordance with fish and kt but was also shown to exclusively detect alterations in known oncogenes and tumor suppressor genes and to identify additional pathogenic aberrations, including chromothripsis and chromoplexy, that were not detected by multiple other cytogenetic methods.
2024-03-07 08:00:00 - Press Release
Bionano Announces Extensive Lineup Of Content At American College Of Medical Genetics And Genomics (acmg) Annual Meeting Including Live Product Showcase Featuring The Company's New Stratys™ System
San diego, march 07, 2024 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo) today announced its participation in the american college of medical genetics and genomics (acmg) annual clinical genetics meeting 2024 with a broad range of content covering optical genome mapping's (ogm) utility for research areas including cancer, rare genetic disease and constitutional disorders. acmg's annual meeting brings together industry, medical, and academic professionals to discuss advances in clinical genetics research. the acmg conference will be held march 12-16, 2024, in toronto, canada.
2024-03-05 16:01:00 - Press Release
Bionano Reports Fourth Quarter And Full-year 2023 Results And Provides Revenue Outlook For 2024
San diego, march 05, 2024 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo) today reported financial results for the fourth quarter and full year ended december 31, 2023 and revenue outlook for 2024.
Latest News
2024-04-25 13:10:24 - InvestorPlace
3 Contrarian Investments to Make Now for Massive Upside Potential
Many investors abandon highly promising shares with little chance of failing. The phenomenon has been exacerbated by overdone fears about elevated interest rates.
2024-02-29 08:00:00 - GlobeNewsWire
Bionano to Present at TD Cowen's 44th Annual Health Care Conference
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano's president and chief executive officer, will present at TD Cowen's 44th Annual Health Care Conference on March 6, 2024.
2024-02-28 08:01:00 - GlobeNewsWire
Bionano to Report Fourth Quarter and Year End 2023 Financial Results and Host a Conference Call and Webcast on March 5, 2024
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 5, 2024, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2023 and to highlight recent corporate progress.
2024-02-07 13:10:32 - InvestorPlace
7 Penny Stocks to Buy on the Dip: February 2024
Now might be a good time to consider scooping up shares of penny stocks to buy on the dip. However, caution is essential, as penny stocks can be volatile and speculative.
2024-01-17 05:53:00 - InvestorPlace
Contrarian Kings: 3 Unloved Stocks That Could Be the Next Market Darlings
On Wall Street zeroes can become heroes relatively quickly. For example, in the past the Street hated Roku (NASDAQ: ROKU ), Intel (NASDAQ: INTC ), Shopify (NYSE: SHOP ) and Pinterest (NYSE: PINS ) and now they're all among the most beloved names in the stock market.
2023-11-17 11:17:22 - Zacks Investment Research
After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO)
Bionano Genomics, Inc. (BNGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2023-11-15 15:23:06 - Seeking Alpha
Bionano Genomics, Inc. (BNGO) Presents at Stifel Healthcare Conference (Transcript)
Bionano Genomics, Inc. (NASDAQ:BNGO ) Stifel Healthcare Conference Call November 15, 2023 1:50 PM ET Company Participants Erik Holmlin - CEO Conference Call Participants Dan Arias - Stifel Dan Arias Okay. Welcome back to the 2023 Stifel Healthcare Conference Day Two.
2023-11-10 05:00:00 - InvestorPlace
3 Stocks That Are Poised to Generate Outsized Returns
In general, stocks generate outsized returns because the Street has been overly bearish on their outlook. Due to the Street's overdone high interest rate concerns, it's now unduly pessimistic about many growth equities with great futures.
2023-11-08 18:58:06 - Seeking Alpha
Bionano Genomics, Inc. (BNGO) Q3 2023 Earnings Call Transcript
Bionano Genomics, Inc. (NASDAQ:BNGO ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants David Holmes - Investor Relations Erik Holmlin - Chief Executive Officer Gülsen Kama - Chief Financial Officer Conference Call Participants Michael Okunewitch - Maxim Group Sung Ji Nam - Scotiabank Jeffrey Cohen - Ladenburg Thalmann Operator Good day, and welcome to the Bionano's Third Quarter 2023 Earnings Conference Call. Today's conference is being recorded.
2023-11-01 08:00:00 - GlobeNewsWire
Bionano to Report Third Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 8, 2023
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2023 and to highlight recent corporate progress.